ProCE Banner Activity

AGILE: Phase III Trial of Ivosidenib + Azacitidine vs Placebo + Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia

Slideset Download
Conference Coverage
In patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive chemotherapy, addition of ivosidenib to azacitidine extended event-free survival in this randomized, placebo-controlled phase III trial.

Released: December 20, 2021

Expiration: December 19, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation